Celularity Inc (CELU)

[subslover]

Oh, Nice! very nice. A couple of excerps from the DR's letter

we expect our advanced biomaterial products and biobanking businesses to achieve net sales percentage growth in the range of 176.1% to 193.0% for the fourth quarter 2023 compared to the fourth quarter 2022. For the full year 2023, we expect net sales percentage growth in the range of 22.7% to 26.6% compared to the full year 2022.

We anticipate shortly that we will announce our expectations for net sales in the first quarter 2024 and the full year 2024, respectively, reflecting three core focuses:


Recently, we took steps to improve our balance sheet and support the growth of our businesses. On Wednesday, 17 January, we announced the closing of two separate financing transactions in which Celularity received combined total gross proceeds of $21 million from a $6 million private placement transaction with our largest single shareholder and a $15 million loan agreement amendment with an existing lender, respectively.